Baker Bros Advisors LP Has Trimmed Bluebird Bio (BLUE) Holding By $5.25 Million; Bwx Tech (BWXT) Sellers Increased By 3.77% Their Shorts

December 7, 2017 - By Adrian Erickson

Bwx Tech Incorporated (NYSE:BWXT) had an increase of 3.77% in short interest. BWXT’s SI was 1.28M shares in December as released by FINRA. Its up 3.77% from 1.23M shares previously. With 474,900 avg volume, 3 days are for Bwx Tech Incorporated (NYSE:BWXT)’s short sellers to cover BWXT’s short positions. The stock decreased 0.36% or $0.22 during the last trading session, reaching $61.29. About 238,510 shares traded. BWX Technologies, Inc. (NYSE:BWXT) has risen 41.41% since December 7, 2016 and is uptrending. It has outperformed by 24.71% the S&P500.

Baker Bros Advisors Lp decreased Bluebird Bio Inc. (BLUE) stake by 14.23% reported in 2017Q2 SEC filing. Baker Bros Advisors Lp sold 50,000 shares as Bluebird Bio Inc. (BLUE)’s stock rose 6.94%. The Baker Bros Advisors Lp holds 301,441 shares with $31.67M value, down from 351,441 last quarter. Bluebird Bio Inc. now has $7.31B valuation. The stock decreased 2.00% or $3.25 during the last trading session, reaching $159.4. About 976,497 shares traded or 25.50% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since December 7, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.




Baker Bros Advisors Lp increased Spring Bank Pharmaceuticals Inc. stake by 153,846 shares to 373,144 valued at $5.05 million in 2017Q2. It also upped Selecta Biosciences Inc. stake by 114,097 shares and now owns 289,809 shares. Ignyta Inc. (NASDAQ:RXDX) was raised too.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.59 earnings per share, up 15.43% or $0.29 from last year’s $-1.88 per share. After $-1.73 actual earnings per share reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -8.09% EPS growth.

Investors sentiment increased to 1.68 in Q2 2017. Its up 0.68, from 1 in 2017Q1. It increased, as 21 investors sold BLUE shares while 53 reduced holdings. 50 funds opened positions while 74 raised stakes. 47.91 million shares or 5.30% more from 45.50 million shares in 2017Q1 were reported. Parametrica reported 0.61% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Tudor Corporation Et Al reported 0.01% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Schwab Charles Investment Mgmt holds 175,532 shares. North Star Invest holds 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 150 shares. Geode Capital Mngmt Ltd Liability Company invested in 0.02% or 373,382 shares. The Pennsylvania-based Stevens Limited Partnership has invested 0.07% in bluebird bio, Inc. (NASDAQ:BLUE). Northern holds 0.02% or 518,673 shares. Tiverton Asset Mngmt Limited Liability Corporation accumulated 29,178 shares. Macquarie Group Ltd reported 11,375 shares stake. Omers Administration Corp invested in 10,100 shares or 0.01% of the stock. Federated Pa holds 0.01% or 17,854 shares in its portfolio. Jabre Prtnrs owns 10,000 shares. Price T Rowe Assoc Md accumulated 2.92 million shares or 0.06% of the stock. Van Eck Corp holds 0.03% or 44,923 shares. Fny Managed Accounts Ltd Liability has 0.07% invested in bluebird bio, Inc. (NASDAQ:BLUE).

Among 24 analysts covering bluebird bio (NASDAQ:BLUE), 15 have Buy rating, 2 Sell and 7 Hold. Therefore 63% are positive. bluebird bio had 69 analyst reports since August 11, 2015 according to SRatingsIntel. JP Morgan maintained the shares of BLUE in report on Monday, August 24 with “Overweight” rating. The firm has “Buy” rating given on Wednesday, November 18 by Goldman Sachs. The firm earned “Outperform” rating on Tuesday, October 20 by Oppenheimer. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Buy” rating by Roth Capital on Thursday, December 3. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, December 7. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Buy” rating by Jefferies on Monday, December 7. Roth Capital maintained the stock with “Buy” rating in Friday, August 28 report. As per Wednesday, May 31, the company rating was maintained by BTIG Research. As per Monday, December 7, the company rating was downgraded by Bank of America. BMO Capital Markets maintained the shares of BLUE in report on Wednesday, August 2 with “Buy” rating.

BWX Technologies, Inc. manufactures and sells nuclear components to the United States government. The company has market cap of $6.09 billion. The firm operates in three divisions: Nuclear Operations, Technical Services, and Nuclear Energy. It has a 31.19 P/E ratio. The Nuclear Operations segment offers precision naval nuclear components and reactors; close-tolerance and equipment for nuclear applications; and components for defense applications, as well as critical nuclear components, fuels, and assemblies for government and other uses.

Among 8 analysts covering BWX Technologies (NYSE:BWXT), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. BWX Technologies had 12 analyst reports since October 13, 2015 according to SRatingsIntel. The rating was reinitiated by KeyBanc Capital Markets with “Overweight” on Tuesday, October 13. The stock has “Neutral” rating by Bank of America on Friday, November 18. The company was initiated on Thursday, January 19 by Suntrust Robinson. As per Tuesday, March 21, the company rating was upgraded by Bank of America. The stock has “Buy” rating by Sidoti on Friday, March 18. As per Thursday, August 10, the company rating was maintained by Bank of America. The rating was initiated by Drexel Hamilton with “Hold” on Friday, April 1. As per Wednesday, November 8, the company rating was maintained by Robert W. Baird. The company was maintained on Thursday, October 5 by Bank of America.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: